AzTrials
AzTrials

Autism Spectrum DisordersASD OutcomeNCT07393152

Pilot Study on Collaborative, Comprehensive, Multidimensional and Quality of Life Tools for Priority Definition, Shared Decision Making, Outcome Evaluation and Quality of Care Improvement in ASD Individuals and Programs in the Real World.

An observational study of Autism Spectrum Disorders, run by Antonella Costantino at 3 sites in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

ASD is a very complex and lifelong disorder. Patients' functioning is influenced by multiple factors, including treatments, inclusion and life contexts. Nonetheless, outcome measures are still point-specific and highly fragmented, rarely considering global or multidimensional functioning, development or long-term… Read more about this study

Who is it for?
Ages 0 to 11 years
Conditions the study is for
Autism Spectrum Disorders
What is being tested?
DD-CGAS (Wagner et al. 2007), Pediatric Quality of Life Inventory (PedsQL). and Child and Adolescent Needs and Strengths (CANS) (Lyons 2022)
How many people
400 participants
Where
3 sitesItaly
Study dates
13 Mar 2025to 31 Oct 2026
How long will I take part?
12 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 11 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Children diagnosed with ASD enrolled in one of the intervention programs in line with the national guidelines, within the partner institutions or other NPIA/rehabilitation services for developmental age of the Lombardy Region are eligible. The overall expected sample is 400 male and female children, under 12 years of age, 200 children aged 0-5 years at T0 and 200 children aged 6-11 years at T0.

Who may be able to join

  • ASD diagnosis according to the criteria shared by the regional NFA network
  • Age under 12
  • Consent from the person holding parental responsibility for health choices

Who cannot join

  • Subjects aged 12 years or older at the time of enrollment
  • No consent from the person holding parental responsibility for health choices

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Italy3 sites, 3 recruiting
  • IRCCS Eugenio Medea- U.O. di Neuropsichiatria infantile - Disturbi del Neurosviluppo

    Bosisio Parini, (LC), 23842

    Massimo Molteni, 3280979411, massimo.molteni@lanostrafamiglia.it

    Recruiting
  • UOSD Disturbo Autistico nel ciclo della vita

    Busto Arsizio, (VA), 21052

    Mariarosa Ferrario, 3392663929, mr.ferrario@asst-valleolona.it

    Mariarosa Ferrario

    Recruiting
  • SC Child and Adolescence Neuropsychiatric Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico , Milan, Italy

    Milan, Michigan, 20122

    Maria Antonella Costantino, +39 02 5503.4400, "Antonella Costantino" <antonella.costantino@policlinico.mi.it>;

    Recruiting

Other trials in Italy

About this study

Official title: Studio Pilota su Strumenti Collaborativi, Globali, Multidimensionali e di qualità Della Vita Per la Definizione Delle priorità, lo Sviluppo di Processi Decisionali Condivisi, la Valutazione Degli Esiti e il Miglioramento Della qualità Delle Cure Per le Persone Con Disturbi Dello Spettro Autistico (ASD) Nella Pratica Clinica Quotidiana.

ASD is a very complex and lifelong disorder. Patients' functioning is influenced by multiple factors, including treatments, inclusion and life contexts. Nonetheless, outcome measures are still point-specific and highly fragmented, rarely considering global or multidimensional functioning, development or long-term modifications, especially in the real world. The present study considers ongoing real-life treatments in three different NHS settings, in line with the Italian Guidelines. Two age classes will be considered, 0-5 and 6-11, adding new outcome tools pre-post intervention to those already used, to evaluate quality of life, global functioning, multidimensional needs and strengths and shared decision making. Correlations between the different outcome tools will be explored, and possible clusters will be investigated. Acceptability of the outcome tools for the operators, patients and families, as well as usefulness and sustainability in daily practice, will also be evaluated.

Being tested
DD-CGAS (Wagner et al. 2007), Pediatric Quality of Life Inventory (PedsQL)., Child and Adolescent Needs and Strengths (CANS) (Lyons 2022)
Keywords
Global functioning, Quality of life, Child and adolescent need and strenght, autism spectrum disorders, Outcome evaluation tools
Medical subject headings
Autism Spectrum Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DD-CGAS (Wagner et al. 2007)Other

    The DD-CGAS is a clinician-completed scale that provides a global rating of the child's functioning. The score refers to the subject's typical functioning during a specified period of time, usually the week prior to the assessment. It is a global assessment based on all available sources of information and all domains of functioning, including self-sufficiency, communication, social behavior, and academic/school functioning. The score should not be influenced by the specific diagnosis, the perceived cause of dysfunction (e.g., cognitive or physical limitation, environmental constraints, behavioral disturbance), or the type and severity of symptoms. The DD-CGAS is a dimensional scale with scores ranging from 1 to 100, with 1 representing the greatest impairment in functioning and 100 representing the best functioning. Each decile (e.g., 1-10, 11-20) has a specific description. The instrument has excellent replicability between raters and temporal stability.

  • Pediatric Quality of Life Inventory (PedsQL).Other

    The PedsQL is designed for children and adolescents between the ages of 2 and 18 years and takes approximately 5 minutes to complete. It is administered as a self-report instrument or via proxy interview. The proxy interview version corresponds to the age of the child (e.g., 2-4 years, 5-7 years, 8-12 years, and 13-18 years). The PedsQL consists of 23 items that assess 4 broad scales, including: physical functioning, emotional functioning, social functioning, and academic functioning. Items are rated using a 5-point Likert scale (0 = never; 4 = almost always), with the total score calculated as the sum of all items considered. PedsQL item scores are inverted and linearly transformed to a 0 to 100 scale, with higher scores indicating a better perception of health-related quality of life. It is important to note that the PedsQL has been validated in children with autism, including parents of children with autism (Vasilopoulou et al. 2016; Perry, N. et al. 2024).

  • Child and Adolescent Needs and Strengths (CANS) (Lyons 2022)Other

    The Child and Adolescent Needs and Strengths scale (CANS) (Lyons 2022) is an open source tool widely used to assess the needs and strengths of children, adolescents, and their families, in clinical, educational and social services settings. It is organized into multiple domains that cover various aspects of a child's life. Common domains include life functioning, behavioral/emotional needs, risk behaviors, strengths, caregiver needs and strengths. Additional modules as trauma can be used.The tool uses a scoring system that reflects the level of need or strength in each area. Typically, needs are rated on a scale from 0 to 3, where 0: No evidence of problems; 1: Watchful waiting, preventive action needed; 2: Action or intervention is required; 3: Immediate or intensive action required. Strengths are rated similarly, with higher scores reflecting greater need for action to support the development of each specific strength.

Study groups in NCT07393152
Study groupRoleWhat they receive
Children aged 0-11 with ASD diagnosisPatients will be enrolled in ongoing treatments in the real context as long as they are in line with the national guidelines for autism, in at least three different national health facilities (SSN) in Lombardy, to represent the variability of the possible organizations of services and interventions, adding new outcome tools.
Receives: Other: DD-CGAS (Wagner et al. 2007); Other: Pediatric Quality of Life Inventory (PedsQL).; Other: Child and Adolescent Needs and Strengths (CANS) (Lyons 2022)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Specific clusters of CANS items that differentiate the profiles of needs and strengths of users at T0.

    The primary objective of the study is to identify specific clusters of CANS items that differentiate the profiles of needs and strengths of users at T0.

    Measured: From March 2025 to August 2026

Secondary outcomes (5)
  1. Correlations between CANS assessment and participants' global functioning (DD-CGAS)

    The outcome measure TAI measured with CANS and expressed as the sum of the actionable items (see section "Groups and Intervention") will be correlated will be correlated with outcome measure quality of life, measured with DD-CGAS expressed as 1-100 score con 1 che rappresenta la maggiore compromissione del funzionamento e 100 il miglior funzionamento

    Measured: From March 2025 to August 2026

  2. Correlations between CANS assessment and participants' quality of life (PEDSQL)

    The outcome measure TAI measured with CANS and expressed as the sum of the actionable items (see section "Groups and Intervention") will be correlated will be correlated with outcome measure quality of life, measured with DD-CGAS expressed as 0-100 score with higher scores on the PedsQL indicating better perceptions of health-related quality of life.

    Measured: From March 2025 to August 2026

  3. Evaluation of changes in children's needs over time based on CANS actionable items.

    Differences between T0 and T1 TAI measeured with CANS and expressed as the sum of the actionable items (see section "Groups and Interventions") will be evaluated using a paired sample t test.

    Measured: march 2025 to august 2026

  4. Evaluation of changes in children's Quality of Life over time.

    Differences between T0 and T1 PedsQL scores (range 0-100, where 0 represents the lowest quality of life and 100 represents the highest quality of life ) will be evaluated using a paired sample t test.

    Measured: from march 2025 to august 2026

  5. Evaluation of changes in children's global functioning

    DESCRIPTION Differences between T0 and T1 DD-CGAS scores (range 1-100, where 1 represents the lowest level of global functioning and 100 represents the highest level of global functioning) will be evaluated using a paired sample t test.

    Measured: from march 2025 to august 2026

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Feb 2026
  2. Study start13 Mar 2025
  3. Primary completion31 Oct 2026 (estimated)
  4. Study completion31 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
400 participants (estimated)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07393152
Sponsor's protocol ID
573_12.03.2025_P_bis
Acronym
ASD Outcome
Status last verified
Jun 2025
First submitted
30 Jul 2025
Last updated
20 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Sandbank M, Pustejovsky JE, Bottema-Beutel K, Caldwell N, Feldman JI, Crowley LaPoint S, Woynaroski T. Determining Associations Between Intervention Amount and Outcomes for Young Autistic Children: A Meta-Analysis. JAMA Pediatr. 2024 Aug 1;178(8):763-773. doi: 10.1001/jamapediatrics.2024.1832.

    PubMed 38913359
  • Provenzani U, Fusar-Poli L, Brondino N, Damiani S, Vercesi M, Meyer N, Rocchetti M, Politi P. What are we targeting when we treat autism spectrum disorder? A systematic review of 406 clinical trials. Autism. 2020 Feb;24(2):274-284. doi: 10.1177/1362361319854641. Epub 2019 Jul 3.

    PubMed 31269800
  • Perry N, Boulton KA, Hodge A, Ong N, Phillips N, Howard K, Raghunandan R, Silove N, Guastella AJ. A psychometric investigation of health-related quality of life measures for paediatric neurodevelopment assessment: Reliability and concurrent validity of the PEDS-QL, CHU-9D, and the EQ-5D-Y. Autism Res. 2024 May;17(5):972-988. doi: 10.1002/aur.3127. Epub 2024 Apr 10.

    PubMed 38597587
  • Ne'eman A. When Disability Is Defined by Behavior, Outcome Measures Should Not Promote "Passing". AMA J Ethics. 2021 Jul 1;23(7):E569-575. doi: 10.1001/amajethics.2021.569.

    PubMed 34351268
  • Jolliffe, I. T. (2002). Principal Component Analysis (2nd ed.). Springer.

  • Godoy PBG, Sumiya FM, Seda L, Shephard E. A systematic review of observational, naturalistic, and neurophysiological outcome measures of nonpharmacological interventions for autism. Braz J Psychiatry. 2022 Nov 5;44(5):532-547. doi: 10.47626/1516-4446-2021-2222. Epub 2022 Jun 24.

    PubMed 35751600
  • Cordell, K. D. et al. (2016). Patterns and priorities of service need identified through the Child and Adolescent Needs and Strengths (CANS) assessment. Children and Youth Services Review, 60, 129-135.

  • Brown, C. C., Wang, E. W., & Goad, C. (2022). A review of the psychometric properties of the child and adolescent needs and strengths (CANS): Perspectives on the present state of the literature and future directions. Residential Treatment for Children & Youth, 39(3), 331-346.

  • Benzoni, S. et al. (2020). Partecipazione e valutazione di esito nella salute mentale in età evolutiva: gli strumenti della famiglia CANS nell'esperienza italiana. Erickson

  • Babamoradi H, van den Berg F, Rinnan A. Confidence limits for contribution plots in multivariate statistical process control using bootstrap estimates. Anal Chim Acta. 2016 Feb 18;908:75-84. doi: 10.1016/j.aca.2016.01.002. Epub 2016 Jan 7.

    PubMed 26826689

Questions about this trial

What is this clinical trial studying?

An observational study of Autism Spectrum Disorders, run by Antonella Costantino at 3 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 20 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Maria Antonella Costantino (+39 02 5503.4400, antonella.costantino@policlinico.mi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Specific clusters of CANS items that differentiate the profiles of needs and strengths of users at T0. (time frame: From March 2025 to August 2026). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07393152, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in